MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good morning, and welcome to the MannKind Corporation Second ...

Westlake Village-based MannKind Corporation is receiving some extra help to advance some of its short and long-term growth strategies. Announced Aug. 6, MannKind, a biotech company focused on inhaled ...

Good morning, and welcome to the MannKind Corporation Second Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded on August 6, 2025, and will be available for ...

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

MannKind Corporation (NASDAQ: MNKD) is one of the best strong buy penny stocks to buy now. In a report released on July 29, ...

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed ...

The biopharmaceutical company posted adjusted earnings of $0.05 per share for the second quarter, matching analyst estimates. However, revenue came in at $76.53 million, below the consensus estimate ...

MannKind Corporation (NASDAQ:MNKD) develops and sells inhaled therapies and delivery devices for serious endocrine and lung diseases. While we acknowledge the potential of MNKD as an investment, we ...

MannKind Corporation (NASDAQ:MNKD) is one of the best biotech penny stocks to buy right now. Analyst Yun Zhong from Wedbush maintained a Buy rating on MannKind Corporation (NASDAQ:MNKD) on June 27, ...

MannKind Corporation (NASDAQ: MNKD) is one of the High Growth Penny Stocks That Are Profitable in 2025. On July 23, RBC Capital’s analyst Douglas Miehm lowered the firm’s price target on MannKind ...